Gene ther­a­py for ovar­i­an can­cer fails PhI­II study — sink­ing biotech's shares

De­spite promis­ing in­ter­im re­sults, VBL Ther­a­peu­tics’ ovar­i­an can­cer drug has ul­ti­mate­ly flopped in a Phase III tri­al.

The Nas­daq-list­ed Is­raeli biotech re­vealed that the OVAL …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER